TSHA

Taysha Gene Therapies Stock Analysis

AI Rating

Low
  • Quality2/10
  • Growth↑ 5/10
  • Value↓ 0/10
Taysha Gene Therapies sales and earnings growth
TSHA Growth
Neutral
  • Revenue Y/Y↑ 17.28%
  • EPS Y/Y↑ 5.56%
  • FCF Y/Y↓ -14.99%
Taysha Gene Therapies gross and profit margin trends
TSHA Profitability
Neutral
  • Gross margin ↑ 100.00%
  • EPS margin↓ -1115.30%
  • ROIC 5Y↓ -780.18%
Taysha Gene Therapies net debt vs free cash flow
TSHA Risk
Great
  • Debt / Equity↓ 0.3
  • Debt / FCF↓ 0.0
  • Interest coverage↓ -1729.1

Taysha Gene Therapies stock volatility is in-line with the overall market. We give it a Great risk rating.

More Biotechnology stocks ↗